폐암 검진 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of lung cancer screening Market

The global lung cancer screening market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.16 billion in 2026, reaching USD 8.67 billion by 2034, registering a CAGR of 9.61% during 2026-2034. North America dominated the market with a 55.13% share in 2025, driven by strong screening programs and advanced healthcare infrastructure.

Lung cancer remains one of the most prevalent and fatal cancers worldwide, primarily linked to tobacco consumption. Early detection through screening plays a critical role in reducing mortality, which is significantly boosting the adoption of advanced diagnostic technologies globally.

Market Trends

Technological Advancements in Screening

The market is witnessing rapid technological progress, particularly in screening methods such as low-dose computed tomography (LDCT), liquid biopsy, and AI-based diagnostic tools. These innovations are improving early detection rates while reducing the need for invasive procedures.

Emerging technologies such as nanoparticle-based sensors and AI-assisted imaging are transforming screening accuracy and efficiency. Additionally, the development of liquid biopsy tests is enabling non-invasive cancer detection, making screening more accessible and patient-friendly.

Market Growth Factors

Rising Prevalence of Lung Cancer

The increasing global incidence of lung cancer, largely due to smoking and lifestyle changes, is a major driver of market growth. Growing awareness regarding early diagnosis and the rising number of screening initiatives by healthcare organizations are further supporting market expansion.

Government programs and awareness campaigns are encouraging high-risk populations to undergo regular screening, thereby increasing the number of diagnostic procedures conducted annually.

Growing Adoption of Advanced Diagnostic Tools

The increasing use of advanced imaging technologies, coupled with favorable reimbursement policies in developed countries, is driving the adoption of screening solutions. Collaborations between biotechnology and healthcare companies are also fostering innovation in diagnostic techniques.

Restraining Factors

High Cost of Screening Tests

Despite technological advancements, the high cost associated with screening procedures, especially CT scans, limits their accessibility in low- and middle-income countries. Limited insurance coverage and inadequate healthcare infrastructure further restrict widespread adoption.

Additionally, the shortage of skilled radiologists and diagnostic professionals in developing regions poses a challenge to market growth.

Market Segmentation Analysis

By Cancer Type

The market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

• The NSCLC segment dominates and is projected to hold 87.8% market share in 2026, owing to its higher prevalence globally.
• The SCLC segment also contributes significantly due to rising awareness and screening initiatives.

By Diagnosis Type

The market is divided into low-dose spiral CT scans and chest X-rays.

• The low-dose CT scan segment dominates with 93.94% share in 2026, driven by higher accuracy and proven mortality reduction benefits.
• Chest X-rays are witnessing declining adoption due to lower effectiveness.

By End-user

The market includes hospitals & clinics and diagnostic centers.

• Hospitals & clinics lead the market, accounting for 70.79% share in 2026, due to better infrastructure and higher patient preference.
• Diagnostic centers are expected to grow steadily with increasing collaborations and service expansion.

Regional Insights

North America

North America accounted for USD 2.11 billion in 2025 and is projected to reach USD 2.31 billion in 2026. Strong screening programs and high disease prevalence support regional dominance.

Europe

Europe held USD 1.15 billion in 2025 and is expected to grow to USD 1.24 billion in 2026. Growth is driven by rising smoking rates and well-established healthcare systems.

Asia Pacific

Asia Pacific generated USD 0.38 billion in 2025 and is projected to reach USD 0.41 billion in 2026. Increasing tobacco consumption and government initiatives are fueling growth.

Rest of the World

• Latin America: USD 0.16 billion (2025) -> USD 0.17 billion (2026)
• Middle East & Africa: USD 0.03 billion (2025) -> USD 0.03 billion (2026)

These regions show gradual growth due to improving healthcare infrastructure.

Key Companies

Leading players in the market include Koninklijke Philips N.V., Siemens Healthineers AG, Canon Medical Systems Corporation, GE Healthcare, and FUJIFILM Holdings Corporation. These companies focus on innovation, product launches, and strategic partnerships to strengthen their market position.

Key Industry Developments

• In 2024, new screening programs and clinical trials were launched to improve early detection.
• AI-based diagnostic tools and imaging technologies received regulatory approvals.
• Companies are increasingly focusing on non-invasive screening solutions such as liquid biopsies.

Conclusion

The lung cancer screening market is poised for strong growth, increasing from USD 3.84 billion in 2025 to USD 8.67 billion by 2034. Rising cancer prevalence, technological advancements, and government support for early diagnosis are key growth drivers. Although high costs and limited accessibility may hinder adoption in some regions, ongoing innovations and expanding screening programs will significantly enhance early detection and improve patient outcomes globally.

Growth Rate CAGR of 9.61% from 2026-2034

Segmentation By Cancer Type

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

By Diagnosis Type

• Low Dose Spiral CT Scan
• Chest X-ray

By End User

• Hospitals & Clinics
• Diagnostic Centers

By Geography

• North America (By Cancer Type, By Diagnosis Type, By End User, and By Country)
  • U.S.
  • Canada
• Europe (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence of Lung Cancer, By Key Region, 2025
• 4.2. Key Industry Developments, Merger, Acquisitions, and Product Launches
• 4.3. Regulatory Scenario Imposed on the Development of Lung Cancer Screening in U.S., Europe, and Asia
• 4.4. Technological Advancements in Lung Cancer Screening
• 4.5. Impact of COVID-19 on Lung Cancer Screening

5. Global Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 5.1.2. Small Cell Lung Cancer
• 5.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 5.2.1. Low Dose Spiral CT scan
  • 5.2.2. Chest X-ray
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Diagnostic Centers
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 6.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 6.1.2. Small Cell Lung Cancer
• 6.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 6.2.1. Low Dose Spiral CT scan
  • 6.2.2. Chest X-ray
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Diagnostic Centers
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 7.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 7.1.2. Small Cell Lung Cancer
• 7.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 7.2.1. Low Dose Spiral CT scan
  • 7.2.2. Chest X-ray
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Diagnostic Centers
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 8.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 8.1.2. Small Cell Lung Cancer
• 8.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 8.2.1. Low Dose Spiral CT scan
  • 8.2.2. Chest X-ray
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Diagnostic Centers
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 9.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 9.1.2. Small Cell Lung Cancer
• 9.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 9.2.1. Low Dose Spiral CT scan
  • 9.2.2. Chest X-ray
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Diagnostic Centers
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Cancer Type
  • 10.1.1. Non-small Cell Lung Cancer (NSCLC)
  • 10.1.2. Small Cell Lung Cancer
• 10.2. Market Analysis, Insights and Forecast - By Diagnosis Type
  • 10.2.1. Low Dose Spiral CT scan
  • 10.2.2. Chest X-ray
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals & Clinics
  • 10.3.2. Diagnostic Centers
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC Countries
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Koninklijke Philips N.V.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Siemens Healthineers AG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GE Healthcare (General Electric Company)
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Nuance Communications, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Eon
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. PenRad Technologies, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Volpara Solutions Limited.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Canon Medical Systems Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. FUJIFILM Holdings Corporation
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Medtronic
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)